Center for Biologics Evaluation and Research (CBER)


The FDA successor to the Bureau of Biologics concerned with Biologic drugs and with the new Protein and Peptide drugs arising from Biotechnology . According to its charter, CBER is responsible for ensuring: • The safety of the U.S. entire blood supply and the products derived from it • The production and approval of safe and effective childhood vaccines, including any future AIDS vaccines • The proper oversight of human tissue for transplantation • An adequate and safe supply of allergenic materials and anti-toxins • The safety and Efficacy of biological Therapeutics , including an exciting new array of biotechnology-derived products used to treat diseases such as cancer and AIDS.